Chengdu Third People's Hospital

Depression leads to complex changes in protein regulation in the brain and other tissues. Reproducibility and data integration remain challenges in this field. We systematically integrated proteomic data from our previous established database Pro-MENDA, encompassing brain, cerebrospinal fluid (CSF), blood, and urine samples from patients with depression. Using a vote-counting statistics to assess consistency of protein expression changes across studies, we identified 2094 different expression proteins from 1804 samples. Functional characterization included Gene Ontology, KEGG pathway enrichment, protein-protein interaction analysis, and post-translational modification. In brain, we observed changes in proteins related to synaptic function and energy metabolism, such as Glial fibrillary acidic protein (GFAP) and Histidine triad nucleotide-binding protein 1 (HINT1). These changes suggest issues with oxidative phosphorylation and synaptic activity. The CSF and blood revealed immune-inflammatory markers like Afamin (AFM) and Serpin Family F Member 1 (SERPINF1), while urine analysis showed signs of neutrophil activation. We also identified 13 shared proteins across brain, CSF, and blood, including Clusterin (CLU), that link complement and coagulation, and reactive oxygen pathways. In this protein-protein interaction network of brain, proteins related to cell adhesion, respiration, neuron and synapse are significantly enriched. Post-translational modifications, particularly phosphorylation, were common. Our findings highlight systemic protein dysregulation in depression. This connects brain and peripheral mechanisms, offering insights for identifying multi-tissue biomarkers and developing targeted therapies.

Abstract The full text of this preprint has been withdrawn by the authors due to author disagreement with the posting of the preprint. Therefore, the authors do not wish this work to be cited as a reference. Questions should be directed to the corresponding author.

Objective: To explore the effect of posterior release surgery combined with halo-pelvic traction in improving spinal deformity and to evaluate the factors affecting the correction rate of scoliosis.Background: Spinal surgery is the preferred treatment for severe scoliosis and kyphosis, but direct primary corrective surgery carries significant risks and demands. Traction surgery has been shown to improve safety and spinal correction rates. However, traction surgery has a ceiling effect. In recent years, posterior release surgery has emerged as an emerging technique for spinal correction, but further research is needed to improve correction rates for severe scoliosis.Methods: Fifty-four patients with spinal deformity treated between April 2021 and December 2023 were divided into two treatment phases: a halo-pelvic traction phase (Phase I) and a posterior spinal release followed by a halo-pelvic traction phase (Phase II). The effects of Phase I and Phase II on scoliosis and kyphosis correction were retrospectively evaluated, and statistical analysis was performed to identify factors influencing scoliosis correction rates.Results: The first-stage scoliosis correction rate was 31.9%, and the kyphosis improvement rate was 23.1%. The second-stage scoliosis correction rate was 25.0%, and the kyphosis improvement rate was 19.5%. The overall scoliosis correction rate was 48.9%, and the kyphosis improvement rate was 38.0%. Statistical analysis showed that age, gender, and comorbidities (rib fusion or spinal fusion) were significant risk factors for scoliosis correction.Conclusion: Posterior release surgery combined with halo-pelvic traction can significantly improve the correction effect of patients with severe spinal deformity.

BackgroundPreoperative oral carbohydrates (CHOs) have been widely utilized to improve perioperative outcomes. However, the effect of postoperative early enteral nutrition (EEN) intervention on patients’ postoperative recovery has yet to be validated by prospective outcomes. This study was designed to investigate the effect of preoperative oral CHOs combined with ENN nutrition on postoperative recovery in patients with colorectal cancer (CRC).MethodsA multicenter, prospective, randomized controlled study was conducted on 331 CRC patients who underwent radical resection from March 1, 2022, to March 1, 2023 and were divided into Group A (preoperative oral CHOs combined with postoperative ENN group, n = 110), Group B (preoperative oral CHOs group, n = 110), and Group C (conventional control group, n = 111) according to the method of the randomized numerical table. The general clinical data, inflammatory indices, nutrition-related serum biomarkers, immune function, postoperative intestinal function recovery, complications and hospitalization length of the three groups were statistically analyzed.ResultsThe baseline characteristics were similar among the groups. In the intention-to-treat analysis, the time to first exhaust (p < 0.05) and defecation (p < 0.05) was significantly shorter in group A than in groups B and C. The total protein (TP) level was significantly greater in group A than in groups B and C on the seventh postoperative day (p < 0.05). In addition, the percentage of T-lymphocytes to lymphocytes on the third postoperative day was greater in Group A than in Groups B and C (p < 0.05), and the length of hospitalization was significantly reduced. However, there was no difference in the incidence of postoperative complications.ConclusionPreoperative oral CHOs combined with postoperative EEN improved serum markers related to postoperative nutrition, enhanced the immunity of the body, and promoted early recovery of intestinal function. Preoperative oral CHOs combined with postoperative EEN is conducive to rapid postoperative recovery and reduces the length of hospitalization.Clinical trial registrationhttps://www.chictr.org.cn/showproj.html?proj=144616, identifier ChiCTR2100054459.

Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), is indicated for the treatment of renal anemia. Its therapeutic mechanism involves stabilizing hypoxia-inducible factor-α (HIF-α), thereby stimulating erythropoietin production and regulating iron metabolism. Recent clinical studies have demonstrated that Roxadustat exhibits efficacy comparable to that of erythropoiesis-stimulating agents (ESAs) in the management of chemotherapy-induced anemia (CIA). However, preclinical studies demonstrate HIF-1α activation promotes tumor progression via multiple pathways (metabolic reprogramming, angiogenesis, metastasis, apoptosis resistance, immune evasion, chemoresistance). Current evidence shows no increased malignancy risk with Roxadustat in renal patients. However, while tumor progression events were reported as treatment-emergent serious adverse events (TESAEs) in CIA studies, clinical data linking Roxadustat to tumor progression remain limited. Furthermore, the observation periods in these studies have been short. A causal relationship remains unestablished due to the insufficient duration of observation required to adequately assess potential HIF-driven oncogenic risks. Consequently, Roxadustat poses a clinical dilemma: its efficacy in CIA offers a promising ESAs alternative, but its HIF-driven oncogenic potential necessitates long-term safety assessment in cancer patients. Future studies must prioritize longitudinal monitoring to define the benefit-risk profile.

Background: Despite percutaneous coronary intervention (PCI) for revascularization, patients with acute coronary syndrome (ACS) still face residual risks of adverse outcomes. Insulin resistance (IR) and renal impairment are independent predictors of poor prognosis in these patients, yet their interaction and underlying mechanisms linked to post-PCI outcomes remain incompletely elucidated. Methods: A retrospective cohort study was conducted involving patients with ACS who underwent PCI at the Third People’s Hospital of Chengdu from July 2018 to December 2020. Insulin resistance (IR) was quantified using the triglyceride–glucose (TyG) index, and renal function was evaluated via the estimated glomerular filtration rate (eGFR). The primary endpoint was major adverse cardiovascular events (MACEs), a composite of all-cause death, non-fatal myocardial infarction, non-fatal stroke, and unplanned revascularization. Multivariable Cox proportional hazards regression and mediation analyses were applied to explore the associations of TyG index and eGFR with patient prognosis, and to quantify the mediating effect of eGFR on the relationship between TyG index and prognosis. Results: A total of 1340 patients with ACS were included in the final analysis. Over a median follow-up duration of 31.02 (interquartile range [IQR]: 27.34–35.03) months, 124 patients (9.25%) experienced MACEs. After adjusting for potential confounders, both the TyG index and eGFR were identified as significant independent predictors of MACEs in the overall population and across predefined subgroups. Specifically, each one-unit increase in the TyG index was associated with a 73.8% higher risk of MACEs (HR 1.738; 95% CI 1.273–2.372), whereas each ten-unit decrease in eGFR was linked to a 12.7% increased MACEs risk (HR 1.127; 95% CI 1.032–1.232). Importantly, after further adjustment for confounders, eGFR significantly mediated 9.63% of the total effect of the TyG index on MACEs risk. Conclusions: Renal impairment partially mediates the association between IR and adverse cardiovascular outcomes in ACS patients undergoing PCI. This finding underscores the clinical importance of the metabolic–cardiorenal axis in this population, suggesting that a comprehensive assessment targeting both IR and renal function-related pathways may enhance risk-stratification accuracy and optimize therapeutic strategies for ACS patients.